Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

This study is currently recruiting participants.

Verified December 2012 by National Cancer Institute (NCI)

Study NCT01502410 Information provided by National Cancer Institute (NCI)

First Received on December 29, 2011. Last Updated on December 4, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Childhood Hepatocellular Carcinoma
Papillary Thyroid Cancer
Recurrent Childhood Liver Cancer
Recurrent Thyroid Cancer

Additional conditions recognized in this trial

Carcinoma
Carcinoma, Hepatocellular
Kidney Neoplasms
Liver Neoplasms
Rhabdomyosarcoma
Rhabdomyosarcoma, Embryonal
Thyroid Diseases
Thyroid Neoplasms
Wilms Tumor

Interventions listed in this trial

sorafenib tosylate
pharmacological study
laboratory biomarker analysis

Additional drug interventions recognized in this trial

Sorafenib

More general drug interventions related to this trial

Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses

Sponsors listed in this trial

National Cancer Institute (NCI)

Back to top of Main Content